The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study
Administering AC was safe for patients who underwent resection for PDAC and encountered challenges in the prompt removal of intraperitoneal drainage beyond 30 days post-surgery. The proactive management of preventing delays in chemotherapy administration could reduce the early recurrence risk in this particular patient cohort.
Authors
- Kuirong Jiang (ORCID: https://orcid.org/0000-0002-2849-5450)
- Jishu Wei (ORCID: https://orcid.org/0000-0003-0529-272X)
- Yang Wu (ORCID: https://orcid.org/0000-0002-0906-9667)
- Kai Zhang (ORCID: https://orcid.org/0000-0003-0042-9109)
- Dong Xu (ORCID: https://orcid.org/0009-0007-6202-3864)
- Yi Miao (ORCID: https://orcid.org/0000-0002-4377-7843)
- Min Tu (ORCID: https://orcid.org/0000-0003-1017-8825)
- Nan Lv
- Qianqian Wang (ORCID: https://orcid.org/0009-0005-9308-0584)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1186/s12885-025-14262-1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China